NCT03980236 (LISA Pilot) is a NA clinical trial of Livongo-Insulia Study App in Type 2 Diabetes Treated With Insulin, sponsored by Livongo Health.

Who is sponsoring NCT03980236?

NCT03980236 is sponsored by Livongo Health.

What drugs are being tested in NCT03980236?

Interventions in NCT03980236: Livongo-Insulia Study App.

What condition does NCT03980236 study?

NCT03980236 studies Type 2 Diabetes Treated With Insulin.

Is NCT03980236 still recruiting?

NCT03980236 is currently terminated. Last updated 18 February 2021.

Last reviewed 2021-02-18 · How we verify

NCT03980236: LISA Pilot

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility of Using the Livongo-Insulia Study App for Patients With Type 2 Diabetes [Pilot Study]

Terminated NA Last updated 18 February 2021

What this trial tests

NA trial testing Livongo-Insulia Study App in Type 2 Diabetes Treated With Insulin in 21 participants. Terminated before completion.

Timeline

6 May 2019

Primary endpoint
27 February 2020

31 May 2020

Quick facts

Lead sponsor	Livongo Health
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	21
Start date	6 May 2019
Primary completion	27 February 2020
Estimated completion	31 May 2020
Sites	1 location across United States

Drugs / interventions tested

Livongo-Insulia Study App

Conditions studied

Type 2 Diabetes Treated With Insulin — all drugs for Type 2 Diabetes Treated With Insulin →

Sponsor

Livongo Health — full company profile →

Who can join

18 and older, any sex, with Type 2 Diabetes Treated With Insulin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Livongo-Insulia Study App Pilot Study (LISA Pilot) is a 3-month, prospective, interventional study. The purpose of this pilot study is to evaluate the feasibility of using the Livongo-Insulia Study App for individuals with type 2 diabetes using basal insulin. This will be assessed by measuring the impact of the Livongo-Insulia Study App on glycemic control for these individuals.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes Treated With Insulin

Currently open trials in the same condition.

NCT07063420 — Patient Centered Multi-Agent Decision Support System (PCM-DSS) for Healthcare Providers · NA · recruiting
NCT05317585 — Continuous Glucose Monitor Use in Pregnancy · NA · recruiting
NCT06311019 — The Effects of CGM and Connected Pen in T2DM Treated With Multiple Daily Insulin Injections · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03980236 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Livongo Health
Last refreshed: 18 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03980236.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing